NO20064964L - Behandling av svekket respiratorisk funksjon - Google Patents

Behandling av svekket respiratorisk funksjon

Info

Publication number
NO20064964L
NO20064964L NO20064964A NO20064964A NO20064964L NO 20064964 L NO20064964 L NO 20064964L NO 20064964 A NO20064964 A NO 20064964A NO 20064964 A NO20064964 A NO 20064964A NO 20064964 L NO20064964 L NO 20064964L
Authority
NO
Norway
Prior art keywords
treatment
respiratory function
impaired respiratory
sleep apnea
impaired
Prior art date
Application number
NO20064964A
Other languages
English (en)
Norwegian (no)
Inventor
Bjarke Ebert
Jonas Lundahl
Jan Hedner
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064964(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20064964L publication Critical patent/NO20064964L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20064964A 2004-04-02 2006-10-30 Behandling av svekket respiratorisk funksjon NO20064964L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55909604P 2004-04-02 2004-04-02
DKPA200400540 2004-04-02
PCT/DK2005/000222 WO2005094820A1 (en) 2004-04-02 2005-03-31 Treatment of impaired respiratory function with gaboxadol

Publications (1)

Publication Number Publication Date
NO20064964L true NO20064964L (no) 2006-10-30

Family

ID=34962889

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064964A NO20064964L (no) 2004-04-02 2006-10-30 Behandling av svekket respiratorisk funksjon

Country Status (9)

Country Link
US (2) US20080269278A1 (de)
EP (1) EP1734956A1 (de)
JP (1) JP2007530604A (de)
AU (1) AU2005229493A1 (de)
BR (1) BRPI0509210A (de)
CA (1) CA2561883A1 (de)
MX (1) MXPA06011325A (de)
NO (1) NO20064964L (de)
WO (1) WO2005094820A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3151832T (pt) 2014-06-06 2021-06-15 Ovid Therapeutics Inc Métodos para aumentar a inibição tónica e tratar a insónia secundária
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
BR112018000933A2 (pt) * 2015-07-17 2018-09-04 Ovid Therapeutics Inc métodos de tratamento de um distúrbio de desenvolvimento
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
EP4233861A3 (de) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Zusammensetzungen zur behandlung von essentiellem tremor
EP3528807A4 (de) * 2016-11-22 2020-06-17 Ovid Therapeutics Inc Verfahren zur behandlung von entwicklungsstörungen und/oder von anfällen mit flupirtin
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
KR20200047557A (ko) * 2017-08-04 2020-05-07 오비드 테라퓨틱스 인크. 당뇨병 및 관련 질환들의 치료에서 가복사돌의 사용
AU2019345312A1 (en) 2018-09-20 2021-03-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
CN113395962A (zh) 2018-11-21 2021-09-14 Certego治疗公司 加波沙朵用于降低自杀风险和快速缓解抑郁症
EP3880201A4 (de) 2018-12-17 2022-07-27 Ovid Therapeutics Inc. Verwendung von gaboxadol zur behandlung von nicht-24-stündiger schlaf-wach-störung
KR20220114572A (ko) 2019-12-18 2022-08-17 오비드 테라퓨틱스 인크. 1p36 결실 증후군의 치료적 치료를 위한 가복사돌
KR20230028244A (ko) 2020-05-20 2023-02-28 썰테고 테라퓨틱스 아이엔씨. 고리 중수소화 가복사돌 및 정신 장애의 치료를 위한 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
WO2000051590A2 (en) * 1999-03-04 2000-09-08 The Board Of Trustees Of The University Of Illinois Neuropharmacological treatment of sleep-related breathing disorders
AR045540A1 (es) * 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)

Also Published As

Publication number Publication date
MXPA06011325A (es) 2006-12-15
EP1734956A1 (de) 2006-12-27
AU2005229493A1 (en) 2005-10-13
US20080269278A1 (en) 2008-10-30
BRPI0509210A (pt) 2007-08-28
US20100093787A1 (en) 2010-04-15
CA2561883A1 (en) 2005-10-13
WO2005094820A1 (en) 2005-10-13
JP2007530604A (ja) 2007-11-01

Similar Documents

Publication Publication Date Title
NO20064964L (no) Behandling av svekket respiratorisk funksjon
NO20052420L (no) Farmakologisk behandling av sovnapn±.
WO2006023703A3 (en) Method for treating sleep related breathing disorders
MX2010002498A (es) Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol.
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
NO20052348L (no) Behandling av hemoragisk sjokk
EA200971053A1 (ru) Способы лечения кожных язв
ATE410163T1 (de) Verfahren zur behandlung und diagnose von atemstörungen im schlaf mit zonisamid und mittel zur durchführung des verfahrens
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
DE60111025D1 (de) Verwendung von Topiramat zur Behandlung und Diagnostizierung von Atemstörungen während des Schlafens und Mittel zur Durchführung der Behandlung und Diagnose
NO20063320L (no) Anvendelse av gaboxadol for behandling av insomni
MA27538A1 (fr) Combinaison synergique comprenant du roflumilast et du (r,r)-formoterol
EA200601853A1 (ru) Лечение нарушенной дыхательной функции
NO20091659L (no) Fremgangsmater for behandling av disruptive oppforselsforstyrrelser
NO20063319L (no) Anvendelse av siramesin i behandlingen av cancer
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
TH138875A (th) อะคลิดิเนียมสำหรับใช้โดยการสูดในการบำบัดโรคทางเดินหายใจ

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104